HOP Jean Minjoz

Besançon 25030

0 studies enrolling now · 7 studies all time

What they study most

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Diabetes Mellitus, Type 1, Gastrointestinal Neoplasms, Heart Failure, Neoplasms, Pancreatic Neoplasms, Secondary Prevention, Stroke

Studies at this site

• This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer — Completed
• A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• Real World Data on Gi(l)Otrif® Dose Adjustment — Completed
• LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment — Completed
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed